NanoBioNexus Expands International Presence with Oxford NanoLabs Letter of Intent
Complete the form below to unlock access to ALL audio articles.
NanoBioNexus has announced that Nanobiotechnology and NanoBioNexus (NBN) will take center stage with the announcement of a recently signed Letter of Intent (LOI) to provide professional services to UK-based Oxford NanoLabs.
The announcement will be made at the NanoBioNexus' second anniversary gala being held Tuesday, July 18, 2006 at San Diego's Salk Institute.
Also unveiled at the event will be a new membership program that is sure to draw attention and additional international membership from the nanobiotechnology community.
Industry thought leaders will join NBN to recognize its 2005 accomplishments, including a review of the group's well-respected educational series.
Among the accomplishments is the expansion of the professional services division which includes clients such as the "Center for Nanotechnology for Treatment, Understanding and Monitoring of Cancer" (NanoTUMOR), one of the Centers of Cancer Nanotechnology Excellence (CCNE) funded by NIH.
"We're honored to announce our agreement with Oxford NanoLabs – highlighting our credibility on the global stage - in addition to kicking-off our unique membership program," said Adriana Vela, NanoBioNexus' founder and chair.
"Our commercial and academic constituencies have validated our philosophy and the quality of work we do on the educational front as well as our professional services."
The LOI agreement is a business instrument outlining terms already agreed upon and is a precursor to a formal contractual agreement with a commercial company.
"After a thorough evaluation we selected NanoBioNexus because of their in-depth understanding of the nanotechnology commercialization process and for their business and scientific expertise," commented Gordon Sanghera, CEO of Oxford NanoLabs.
"We look forward to NanoBioNexus assistance in establishing a corporate presence in the United States and helping us to reach our goals for our Nanopore Technology."
Companies and individuals in the nanotech sector regularly seek ways to expand their businesses, relationships and knowledge.
The NBN membership program uniquely addresses those needs by serving as a vehicle by which they can expand their reach, share information and network in order to promote and grow their business.
"NanoBioNexus listened to its constituents' requests and has developed a membership program that offers excellent benefits for small businesses and individuals," says Vela.
"In addition to discounts for seminars, webcasts, and other services, we will also provide small business members brand building and public relations opportunities as well as access to nanobiotech thought leaders and the opportunity to forge powerful relationships."
Companies that already joined include Oxford NanoLabs and nanoComposix Inc. and many more expected to sign up.
NanoBioNexus will soon begin providing the second year activities of the educational service component for the NCI funded Cancer Center of Nanotechnology Excellence (CCNE) partnership that includes the University of California, San Diego, UCSD Moores Cancer Center, the Burnham Institute, NanoBioNexus, and the University of California campuses at Irvine, Riverside and Santa Barbara.
The upcoming educational seminars of the NanoTUMOR are slated for both the general public and the healthcare communities in nanotechnology.
Additionally, NBN staff is designing the concept, content and scope of the CCNE's educational website and will oversee the launch of that website at the end of August.
NanoBioNexus will continue its ongoing series of events that are open to the general community.
The next NBN seminar, "Canada's Nanotech Innovation and Commercialization Models" begins September 14, 2006.
Other educational activities include providing bylined content to NanoBiotech News and yearly subscriptions to this leading-edge publication.
Other editorial submissions include a feature article discussing "NBN's Community Building" in the May issue of NanoNews-Now written by Julian Zegelman, NBN's Director of Corporate Partnerships and Alliances.
That same issue of NanoNews-Now included an interview with the CCNE and NBN principals.
Additionally, the NBN executive team authored Drug Delivery Technology's cover feature on "Nanodrugs" for the May issue.
